Login to Your Account

Therapies Can Have Broader Utility than Screens Identify

By Anette Breindl
Science Editor

Friday, December 7, 2012

One of the challenges of targeted therapies is to figure out who will benefit from them. In data presented at the San Antonio Breast Cancer Symposium, clinicians identified a group of breast tumors that did not overexpress HER2, but nevertheless were sensitive to HER2 inhibitors

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription